Empire Resorts (NYNY): “Resorts World Catskills in Sullivan Cou...

“Resorts World Catskills in Sullivan County is looking

Soco54 · 2019-06-19T17:36:48.1630000Z

“Resorts World Catskills in Sullivan County is looking forward to the impact of sports betting after the New York State Gaming Commission voted on regulations this week. The practice, deemed legal by the Supreme Court a year ago, was approved for four upstate casinos. Now county officials are hoping that will translate into more business for the facility. It's been operating with large deficits, but Sullivan County Partnership President Marc Baez said he's expecting sports betting to change that. "We're hoping it's going to attract more people to the casino, different people that might not otherwise come for this particular reason,” said Resorts World Catskills President Marc Baez. “And expose them to other assets of Sullivan County that we certainly want people to come and cherish and participate in." Each casino will need to obtain a wagering license in order for sports betting to begin. That is expected to happen later this summer” https://www.baynews9.com/fl/tampa/business/2019/06/13/resorts-world-catkills-banking-on-sports-betting-to-improve-business

Play Episode

9min

Proactive - Interviews for investors

Fineqia International CEO unveils first DeFi yield ETP

Fineqia International Inc (CSE:FNQ, OTC:FNQQF) CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell

Proactive - Interviews for investors

Light Science Technologies CEO on Injecta Fire Barrier solution to UK's unsafe cladding dilemma

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the significant opportunity surrounding the company’s Injecta Fire Barrier solution, particularly in light of ongoing fire safety issues in the UK’s residential building sector. Deacon highlighted that the UK still has more than 33,000 buildings between 11m and 18m in height, and over 11,000 high-risk buildings above 18m, that require urgent fire protection measures. He referenced a government estimate suggesting a potential £22 billion cost to address the cladding crisis, which has persisted since the Grenfell tragedy. The Injecta Fire Barrier, acquired in late 2023, offers what Deacon described as a "unique solution"—one that avoids facade removal by injecting fire-resistant material directly into cavities, providing over two hours of fire resistance. He said, "We're three times less in cost and much quicker to install than traditional methods." He noted the division secured £2.7 million in orders during 2024, performing strongly and receiving positive feedback for its efficiency and clean delivery. With an average order value over £500,000 and significant market scope, Deacon framed the opportunity as a scalable revenue driver for the group. The company is targeting £50 million in revenue over the next five years, with Injecta Fire Barrier expected to be a key growth driver. 👉 For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #FireSafety #BuildingSafety #InjectaFireBarrier #LightScienceTechnologies #GrenfellLegacy #PropertyInvestment #ConstructionInnovation #FireProtection #CladdingCrisis #UKHousingSafety #ProactiveInvestors #SimonDeacon #BuildingRegulations #RealEstateSafety #PassiveFireProtection

Proactive - Interviews for investors

Acusensus talks global expansion and growth drivers

Acusensus Ltd Managing Director talked with Proactive at AIM's Small and Midcap Conference about the company’s progress in road safety technology, its global expansion, and the upcoming launch of a new product line aimed at road worker protection. Alex Jannink, Managing Director and Co-founder of Acusensus, explained how the company pioneered enforcement cameras targeting behaviours like mobile phone use and seatbelt compliance. “We supply these automated enforcement cameras...and we receive a fixed monthly fee essentially for those services,” he said, outlining the company's outsourced business model under long-term government contracts. While 93% of revenues currently come from Australia, Jannink confirmed growth is underway internationally, with active customers in the United States and United Kingdom. Acusensus has also secured a nationwide speed enforcement contract in New Zealand, expected to contribute significantly from the next financial year. Jannink highlighted the broader social mission behind the business: “The whole goal of the company is to change behaviours and to save lives.” He pointed to strong behavioural impacts from previous deployments, including a six-fold drop in mobile phone use and a 21% reduction in road fatalities in New South Wales. A new road worker safety product line is also in development and, according to Jannink, “can be as large as the enforcement business.” #Acusensus #RoadSafety #AItechnology #TrafficEnforcement #DriverSafety #ASXStocks #GovernmentContracts #InfrastructureSafety #SmartCameras #RoadWorkerProtection #AutonomousTech #InvestSmart #PublicSafetyTech

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Followers	36
Posts	3353
Boards Moderated	1
Alias Born	11/13/2013

Volume:	-
Day Range:
Bid:	9.73
Ask:	9.78
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

NYNY Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free